JMJohn Munkhaugen

John Munkhaugen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John Munkhaugen has a total of 168 co-authors. Here are the top co-authors by number of shared publications:

  • Toril Dammen

    Division of Mental Health and Addiction, Department of Research and Innovation, Oslo University Hospital , Sognsvannsveien 2, 0372 Oslo

    10 shared publications
  • Einar Husebye

    Department of Medicine, Drammen Hospital, Vestre Viken Trust , Dronninggata 48, 3004 Drammen

    8 shared publications
  • Dan Atar

    Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    7 shared publications
  • Elise Sverre

    Department of Medicine, Drammen Hospital, Vestre Viken Trust , Dronninggata 48, 3004 Drammen

    7 shared publications
  • Erik Gjertsen

    Medisinsk avdeling, Drammen sykehus, Vestre Viken

    7 shared publications
  • Jan Erik Otterstad

    Department of Cardiology, Vestfold Hospital Trust , Vestfold

    7 shared publications

Latest Publications

  • Open Access

    Beta-blocker therapy and angina burden after myocardial infarction: A prespecified substudy of the BETAMI-DANBLOCK trial

    by Anna Meta Dyrvig Kristensen, Therese Lucia Friis Holmager, Frida Rykind-Eriksen, Morten Wang Fagerland, Sigrun Halvorsen, Michael Hecht Olsen, Arnhild Bakken, Dan Atar, John Munkhaugen, Eva Prescott

    Aims: The effect of beta-blockers initiated after myocardial infarction (MI) on subsequent angina burden remains uncertain. Methods and results: This pre-specified BETAMI-DANBLOCK substudy included patients with MI and left ventricular ejection fraction (LVEF)≥40% randomized to beta-blockers or no beta-blockers. Endpoints comprised angina-related hospital contacts/diagnostic ischemia tests, coronary revascularization, anti-anginal medications (≥2 prescriptions for calcium-channel blockers/nitrates), and patient-reported angina symptoms [Canadian Cardiovascular Society (CCS) class 0-4]. Subdistribution hazard ratios (SHR) were estimated by Fine-Gray models. Anti-anginal prescriptions were compared using 95% confidence intervals (CI) for differences in proportions. A total of 5574 patients were randomized to beta-blockers (n=2783, median dose 50 mg metoprolol) or no beta-blockers (n=2791). During median 3.5 years follow-up, an angina-related hospital contact/diagnostic ischemia test occurred in 724 patients (26.0%) in the beta-blocker group vs. 834 (29.9%) in the no beta-blocker group (SHR 0.85; 95% CI, 0.77-0.94). Coronary revascularization occurred in 108 (3.9%) vs. 110 patients (3.9%)(SHR 0.99; 95% CI 0.76-1.29). Fewer patients in the beta-blocker group were treated with calcium-channel blockers [630(22.7%) vs. 738(26.6%); -3.9 percentage points (95% CI, -6.2 to -1.6)], whereas nitrate use [342(12.3%) vs. 356(12.8%); -0.5 (95% CI, -2.2 to 1.2)] and CCS-scores were similar between groups (difference in change at 12-months, -0.04; 95% CI, -0.14-0.05). Conclusions: In patients with MI and LVEF≥40%, a moderate dose of beta-blockers was associated with a lower incidence of first angina-related hospital contact/diagnostic ischemia testing, and lower use of calcium-channel blockers. The absence of differences in coronary revascularization, nitrate use and patient-reported angina symptoms suggests that the overall benefit on angina is limited.

  • Open Access

    Impact of beta-blockers on quality of life in patients with myocardial infarction without heart failure: A prespecified substudy of the DANBLOCK trial

    by Frida Rykind-Eriksen, Anna Meta Dyrvig Kristensen, Therese Holmager, Harun Caglar, Johanne E Nyen, Ann-Dorthe Zwisler, Jess Lambrechtsen, Svend E Jensen, John Munkhaugen, Eva Prescott

    Background and Aims: Contemporary evidence on the effects of beta-blockers on health-related quality of life (HRQoL) after myocardial infarction (MI) in patients without heart failure is limited, despite widespread use. In this prespecified substudy of the DANBLOCK trial, we aimed to assess whether beta-blocker therapy influences HRQoL after MI in patients with left ventricular ejection fraction (LVEF) >40%. Methods: Patients with a recent (≤14 days) MI and LVEF >40% were randomised to open-label beta-blocker therapy or no beta-blocker. HRQoL was assessed at baseline and at three-, 12-, and 24-months using the EQ-5D-5L questionnaire and the EQ visual analogue scale (EQ VAS). The primary endpoints were between-group differences in change from baseline to each follow-up visit estimated by a linear mixed-effects model. Results: Among 2707 randomised patients, 2681 (99%) completed at least one EQ-5D-5L questionnaire. Median EQ-5D and EQ VAS scores at baseline were 0.95 (Interquartile range [IQR]: 0.87-1.00) and 77 (IQR: 65-87), respectively. Scores remained stable throughout follow-up. No significant between-group differences for EQ-5D index score and EQ VAS score were observed at any time point. At 12 months, mean difference (beta-blocker minus no beta-blocker) in EQ-5D index- and EQ VAS score was -0.001 (95% confidence interval [CI], -0.016 to 0.013, P=0.86) and -1.35 (95% CI, -2.85 to 0.15, P=0.08), respectively. Results were consistent in prespecified subgroups (age, sex, type of MI, and LVEF). Conclusion: Overall, a high HRQoL was observed among post-MI patients. Beta-blocker therapy did not affect HRQoL after MI in patients without heart failure.

  • Risk-score guided estimation of absolute benefit from beta-blockers after myocardial infarction in patients without heart failure: a substudy of the BETAMI-DANBLOCK trial

    by Harun Caglar, Therese Holmager, Anna Meta Dyrvig Kristensen, Arnhild Bakken, Frida Rykind-Eriksen, Peter Deeg, Kristoffer Andresen, Michael Maeng, Erik Øie, Dan Atar, et al.

    Aims: To assess whether a modified clinical risk score can stratify baseline risk and estimate expected absolute benefit from beta-blocker therapy in post-MI (myocardial infarction) patients with LVEF (left ventricular ejection fraction) ≥ 40%. Methods and results: This substudy of the BETAMI-DANBLOCK trial included patients with a recent MI and LVEF ≥40% who were randomized to beta-blocker or no beta-blocker therapy. A modified Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P) was constructed, and patients were categorized as low-, intermediate-, or high-risk. The primary outcome was a composite of all-cause mortality, new MI, unplanned coronary revascularization, ischaemic stroke, heart failure, or malignant ventricular arrhythmia. Treatment effects across TRS-2P strata were estimated using Cox proportional hazards and Fine-Gray subdistribution hazard models. Three-year absolute risk reduction (ARR) and number needed to treat (NNT) were calculated for each risk stratum. Among 5558 patients, 38.4% were classified as low risk, 52.8% as intermediate risk, and 8.8% as high risk. Event rates increased stepwise with higher modified TRS-2P, with no evidence of heterogeneity in the relative treatment effects across risk strata (hazard ratios: 0.88, 0.81, and 0.88, respectively). However, the score translated the modest relative effects into clinically distinct absolute benefits: Three-year ARR was 1.4% {NNT = 72 [95% confidence interval (CI): 41–361]} in low-risk, 2.1% [NNT = 47 (95% CI: 27–239)] in intermediate-risk, and 3.6% [NNT = 28 (95% CI: 16–140)] in high-risk patients. Conclusion: The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%. Trial registration number: NCT03646357 and NCT03778554

  • Open Access

    Beta-blocker therapy and physical activity after myocardial infarction: a preplanned sub-study of the BETAMI trial

    by Erik Madssen, Elise Sverre, Johanne E Nyen, Therese L F Holmager, Anna M D Kristensen, Arnhild Bakken, Jarle Jortveit, Thor Edvardsen, Terje Steigen, Sigrun Halvorsen, et al.

    Aims: To investigate the effect of long-term beta-blocker therapy on physical activity (PA) level after myocardial infarction (MI) in patients without heart failure. Methods and results: The BETAMI trial randomized patients hospitalized with a MI without heart failure (LVEF ≥40%) to beta-blocker or no beta-blocker. In this preplanned sub-study, PA level was assessed by guideline-recommended PA level (≥30 min moderate activity ≥5 days/week) or not and self-reported hours/week with light to moderate and vigorous PA. Between-group differences in PA from baseline before randomization to 18-months were estimated by linear mixed models. Exploratory analysis assessed treatment effects on a composite of all-cause mortality and major adverse cardiovascular events using a Cox proportional hazards model. Of the 2867 randomized patients, 2185 (76%) responded to the PA questions and were included in this analysis. Mean age was 62.5 (SD 10.1) years, and 20.6% were women. No differences in guideline-recommended PA level or mean hours of light to moderate and vigorous PA were reported between the beta-blocker and non-beta-blocker group at baseline or during 18-month follow-up. At 12-month follow-up, 37.0% in the beta-blocker group and 36.7% in the no beta-blocker group reported guideline-recommended PA level (OR 0.97, 95% CI 0.69–1.37). Exploratory, hypothesis-generating analyses did not demonstrate a statistically significant interaction (P for interaction = 0.06) between treatment assignment and baseline PA level for recurrent clinical events. Conclusion: Beta-blocker therapy did not result in a change in PA level in post-MI patients without heart failure during the 18-month follow-up. Registration: ClinicalTrials.gov. URL: https://clinicaltrials.gov/search?term==NCT03646357. Unique identifier: NCT03646357, registered on 23 August 2018.


  • Open Access

    Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model

    by Joris Holtrop, Mari N Gynnild, Salil V Deo, Carl-Emil Lim, Stelios Boulitsakis Logothetis, Kristi Läll, Minna Oksanen, Håvard Dalen, John Munkhaugen, Peter Ueda, et al.

    Background and Aims: The 2021 ESC guidelines on cardiovascular (CV) disease prevention recommend the SMART-REACH lifetime risk model to guide treatment decisions in patients with established atherosclerotic CV disease. The aim was to develop the SMART-REACH2 model for estimating lifetime risk of recurrent CV events and treatment benefits in patients with established atherosclerotic CV disease, with systematic recalibration to the four European and other global risk regions. Methods: SMART-REACH2 was derived in 8708 individuals aged 40–90 years with coronary, cerebrovascular, peripheral artery disease and/or abdominal aortic aneurysm from the UCC-SMART cohort. Sex-stratified, cause-specific Cox models for recurrent CV events and non-CV death were fitted using age as timescale and routinely available predictors. Recurrent CV events were defined as a composite of myocardial infarction, stroke, or CV death. Recalibration was based on representative cohorts per risk region. External validation was performed in 2 085 780 patients from 54 countries; model performance was assessed by calibration plots and Harrell's C-statistic. Results: In the derivation cohort, 2057 recurrent CV events occurred over a median follow-up of 8.5 years (25th–75th: 4.3–13.0). In external validation, 307 706 events occurred. The pooled C-statistic was 0.68 (95% confidence interval 0.66–0.69) and ranged from 0.66 (0.64–0.69) for European low-risk region up to 0.72 (0.66–0.78) for Latin America, with adequate calibration across risk regions. Performance was consistent across sexes and CV disease subtypes. Using SMART-REACH2, estimated potential gains in CV disease-free life expectancy for a 50-year-old example patient receiving intensified preventive treatment (15 mmHg systolic blood pressure and 1.0 mmol/L low-density lipoprotein cholesterol reduction) ranged from 2 years in the low-risk region to 4.4 years in the very-high-risk region. Conclusions: The updated SMART-REACH2 model accounts for geographical and sex-specific variations and allows estimation of short-term and lifetime risk of recurrent CV events and treatment benefits, facilitating shared decision-making as recommended by guidelines.


  • Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population

    by Anna Meta Dyrvig Kristensen, Jarle Jortveit, Therese Holmager, Dan Atar, Michael Hecht Olsen, Arnhild Bakken, Terje Steigen, Henrik Schirmer, Thor Edvardsen, Alf Inge Larsen, et al.

    Background and Aims: In patients with myocardial infarction (MI), no heart failure, and left ventricular ejection fraction (LVEF) ≥ 40%, the combined BETAMI-DANBLOCK trial showed that beta-blockers reduced the risk of all-cause mortality or major adverse cardiovascular events. This study evaluated the representativeness of the trial. Methods: Participants in BETAMI (n = 2867) and DANBLOCK (n = 2707) were compared with a cohort of revascularized MI patients with LVEF ≥40%, and no heart failure from the Norwegian Myocardial Infarction Registry (the NORMI cohort)(n = 20 804). Baseline characteristics were evaluated, and absolute risks of all-cause mortality and/or MI were estimated. A transportability analysis was conducted by weighting the BETAMI-DANBLOCK population according to the NORMI cohort. Results: Median age was 66 years (interquartile range [IQR]: 57–74) in the NORMI cohort and 63 years (IQR: 55–70) in BETAMI and DANBLOCK. Patients in the NORMI cohort had a higher prevalence of diabetes, previous coronary artery disease, and LVEF 40–49%, compared with trial participants. At 3-year follow-up, the absolute risk of all-cause mortality or MI was 12.0% in the NORMI cohort, 7.7% in BETAMI, and 7.8% in DANBLOCK. Corresponding risks of MI were 6.3%, 5.6%, and 4.3%, respectively. The treatment effects of beta-blockers were similar when the trial population was weighted according to the characteristics of the NORMI cohort. Conclusions: Compared with the NORMI cohort, participants in BETAMI and DANBLOCK were younger, had a lower proportion of certain comorbidities, and experienced a lower risk of all-cause mortality and MI. Despite these differences, the effect of beta-blockers remained consistent when the trial population was weighted according to the NORMI cohort.


  • Validating national registry data for randomized trials: comparison of registry-derived cardiovascular events with and without adjudication in the BETAMI-DANBLOCK trial

    by Therese Lucia Friis Holmager, Anna Meta Dyrvig Kristensen, Morten Wang Fagerland, Dan Atar, Michael Hecht Olsen, Arnhild Bakken, John Munkhaugen, Eva Prescott

    Aims: Registry-based randomized clinical trials are increasingly applied in clinical research, providing advantages in feasibility and data capture. However, registry-based data may introduce bias through misclassification or missing information. Methods and results: In the BETAMI-DANBLOCK trial, 5574 patients with myocardial infarction (MI) and no heart failure were randomized to beta-blocker or no beta-blocker therapy. The primary endpoint events (all-cause mortality, MI, ischemic stroke, heart failure, unplanned coronary revascularization, and malignant ventricular arrhythmias) were identified from the Danish/Norwegian national patient registries, self-reported questionnaires, and medical records. All registry-identified events, except all-cause mortality, underwent blinded adjudication. We compared non-adjudicated and adjudicated events by calculating incidence rates and hazard ratios (HRs) for beta-blocker therapy vs. controls. National registries captured 99.7% of primary endpoint events registered by self-report and medical records. Of the primary endpoint events identified through the registries, 75% were confirmed by adjudication (incidence rate 6.23 vs. 4.43/100 person-years). The confirmation rate was lower during the first 6 months and varied by event type (from 92% for ischaemic stroke to 45% for unplanned coronary revascularizations and heart failure). Estimated treatment effects were consistent for the primary endpoint with non-adjudicated and adjudicated events (HR 0.88, 95% confidence interval (CI): 0.78–0.98 and HR 0.85, 95% CI: 0.75–0.98, respectively), with no apparent differences across event types except for heart failure and revascularization. Conclusion: Registry data provided effect estimates of beta-blockers comparable to adjudicated data. However, adjudication substantially reduced the number of cardiovascular endpoint events and event-specific misclassification appeared, particularly during the first months after the index event. Trial registration number: BETAMI-DANBLOCK ClinicalTrials.gov numbers, NCT03646357 and NCT03778554


  • Open Access

    Beta-blockers, depression, and anxiety after myocardial infarction: the BETAMI-DANBLOCK trial

    by Johanne E Nyen, Anna Meta D Kristensen, Toril Dammen, Ann-Dorthe Zwisler, Michael Hecht Olsen, Michael Maeng, Sigrun Halvorsen, Kjell Vikenes, Arnhild Bakken, Therese Holmager, et al.

    Symptoms of depression and anxiety are common among patients with myocardial infarction (MI) and associated with reduced health-related quality of life and increased risk of recurrent major adverse cardiovascular events.1,2 The underlying causes of post-MI depression and anxiety are still a matter of elucidation.3 They may be pre-existing conditions caused by environmental, biological or genetic factors, as well as a response to the MI event itself and/or side effects of the treatments initiated.3


  • Open Access

    Cardiac-related symptoms in individuals aged ≥65 years without diagnosed cardiac disease: insights from the NORSCREEN trial

    by Jarle Jortveit, Miroslav Boskovic, Marius B Haraldsen, Trygve Berge, Bjørnar L Grenne, John Munkhaugen, Sigrun Halvorsen

    Aims: Population-based data on cardiac-related symptoms in individuals without diagnosed cardiac disease remain limited, despite important implications for early detection and management. We aimed to assess the prevalence of self-reported symptoms and the association with quality of life (QoL) among adults aged ≥65 years with ≥1 additional stroke risk factor, but without diagnosed cardiac disease. Methods and results: This is a cross-sectional study of the NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial population at baseline. NORSCREEN is an ongoing, nationwide, randomized atrial fibrillation screening study in adults aged ≥65 years at increased risk of stroke (CHA2DS2-VA ≥2). All participants completed a baseline questionnaire capturing clinical information, symptoms, and QoL. Of the 50 549 participants enrolled from 2023 to 2025, 39 281 (78%) reported no diagnosed cardiac disease. Among those, 17 069 (43%) reported cardiac-related symptoms compared to 7551 (67%) of 11 268 individuals with known cardiac disease. The most common symptoms were fatigue, exertional dyspnoea, and tachycardia. Female sex [adjusted odds ratio 1.66, (95% CI 1.58–1.75)], physical inactivity [1.43 (1.32–1.55)], current smoking [1.24 (1.12–1.37)], age <75 years [1.14 (1.08–1.20)], living alone [1.13 (1.07–1.20)], and comorbidities including chronic obstructive pulmonary disease [6.51 (5.63–7.54)] and anxiety [3.99 (3.64–4.38)] were associated with cardiac-related symptoms. Symptomatic individuals reported significantly lower RAND-36 QoL scores across all domains compared to those without symptoms. Conclusion: In this cohort of individuals aged ≥65 years at increased risk of stroke, but without diagnosed cardiac disease, nearly half reported cardiac-related symptoms, which were associated with substantially reduced QoL. These findings suggest there might be unmet needs in identifying and managing cardiovascular disease. Registration: Clinical trials: NCT05914883

  • Open Access

    Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score

    by Joris Holtrop, Mari N Gynnild, Matthew Richards, Carl-Emil Lim, Mitja Lääperi, Salil V Deo, Håvard Dalen, Peter Ueda, Sanjay Rajagopalan, Małgorzata Chlabicz, et al.

    Aims: Guidelines recommend using the SMART2 model, estimating the risk of recurrent cardiovascular (CV) events, to support treatment decisions in patients with established atherosclerotic CV disease (ASCVD). They further outline that adding biomarkers, comorbidities, anthropometric, and social factors may improve these predictions. This study aims to investigate the added predictive value of guideline-outlined factors including biomarkers, comorbidities, anthropometric, and social factors on top of the SMART2 model using an approach enabling their use as add-on predictors. Methods and results: Patients aged 40–80 with ASCVD were included from 11 cohorts (n = 179 382 with 25 789 recurrent CV events). Additional factors included biomarkers [troponin I, N-terminal pro-B-type natriuretic peptide (NT-proBNP), albuminuria], comorbidities (heart failure, atrial fibrillation, coronary multivessel disease), anthropometric measurements [body mass index (BMI), waist and hip circumference], social (employment, education), and other factors (former smoking, parental CV history). Cross-cohort availability of these factors ranged from two cohorts for albuminuria to all cohorts for BMI. These factors were assessed as add-on predictors to the SMART2 model using Fine–Gray models with SMART2 coefficients as offset with recurrent CV events as the primary outcome (non-fatal myocardial infarction or stroke, or CV death). Added predictive value was assessed through cohort cross-validation by change (Δ) in C-statistic, calibration, and net benefit through decision curve analysis. Subdistribution hazard ratios for additional factors ranged from 0.77 (95% confidence interval 0.75–0.80) for employment status to 1.69 (1.63–1.76) for heart failure history. ΔC-statistic was largest for NT-proBNP [0.0127 (0.0060–0.0193)] and troponin I [0.0100 (0.0020–0.0181)], with statistically significant but smaller ΔC-statistics for employment, heart failure, and atrial fibrillation. Calibration was adequate before and after integration of additional factors. Decision curve analysis demonstrated added net benefit beyond SMART2 for NT-proBNP, heart failure history, atrial fibrillation, albuminuria, current employment, coronary multivessel disease, and education level across clinically relevant thresholds up to 40% predicted risk. Conclusion: The flexible add-on of guideline-outlined factors on top of SMART2 enables more personalized and improved estimation of recurrent CV event risk in patients with established ASCVD.